Insomnia is a common disorder linked with adverse long-term medical and psychiatric outcomes. The underlying pathophysiological processes and causal relationships of insomnia with disease are poorly understood. Here we identified 57 loci for self-reported insomnia symptoms in the UK Biobank (n = 453,379) and confirmed their effects on self-reported insomnia symptoms in the HUNT Study (n = 14,923 cases and 47,610 controls), physician-diagnosed insomnia in the Partners Biobank (n = 2,217 cases and 14,240 controls), and accelerometer-derived measures of sleep efficiency and sleep duration in the UK Biobank (n = 83,726). Our results suggest enrichment of genes involved in ubiquitin-mediated proteolysis and of genes expressed in multiple brain regions, skeletal muscle, and adrenal glands. Evidence of shared genetic factors was found between frequent insomnia symptoms and restless legs syndrome, aging, and cardiometabolic, behavioral, psychiatric, and reproductive traits. Evidence was found for a possible causal link between insomnia symptoms and coronary artery disease, depressive symptoms, and subjective well-being.
Letters

Nature GeNetics
was observed for previously reported CYLC1 (P = 9.0 × 10 −3 ). The TMEM132E and SCFD2 signals showed a concordant direction of effect in both UK Biobank subsamples but were not significant, a finding perhaps reflecting selection bias in the interim-release sample 17 . No other findings from previous candidate-gene association studies or smaller GWAS were confirmed (Supplementary Table 4 ).
Secondary GWAS excluding current shift workers or individuals reporting use of hypnotic, antianxiolytic, or psychiatric medications, and/or having selected chronic diseases or psychiatric illnesses (excluding n = 76,470 participants) revealed strong pairwise genetic correlation to the primary GWAS (r g ~1) and did not identify additional association signals ( Supplementary Figs.  1-3 ). Thus, biological processes underlying the pathophysiology of insomnia symptoms may be common between the general population and those with comorbidities, in accordance with the recent clinical reclassification of primary and secondary insomnia diagnoses into an insomnia disorder 18 .
The prevalence of insomnia symptoms varies by sex; therefore, we performed secondary sex-stratified GWAS (Supplementary Table  5 ). As described previously 15, 16 , the genetic architecture for frequent insomnia symptoms differed by sex, and we observed a genetic correlation between the stratified GWAS of r g = 0.807 ( Supplementary  Fig. 3 ). We found 13 additional loci (eight in women and five in men), although there were no genome-wide-significant sex interactions. The effects in women were not modified by menopausal status ( Supplementary Table 5 ).
Self-reporting of insomnia symptoms has limitations, including recall bias and lack of granularity 19 . Therefore, we sought replication of association signals in the HUNT population study with self-reported insomnia symptoms 20 (n = 14,923 cases and 47,610 controls; Supplementary Table 6 ) and the Partners Biobank with physician-diagnosed insomnia (n = 2,217 cases and 14,240 controls). Replication was observed for the MEIS1 variant in both cohorts, and a genetic risk score (GRS) using our 57 variants and weighted by the effect estimates from GWAS of frequent insomnia symptoms (provided in Supplementary Table 2 ) was also associated with insomnia symptoms in HUNT (OR (95%CI) = 1.015 (1.01-1.02) per allele, P = 2.71 × 10 −11 ) and the Partners Biobank (OR (95%CI) 1.017 (1.007-1.027) per allele, P = 8.88 × 10 −4 ) ( Table 1 and Supplementary Table 8 ). A meta-analysis of the UK Biobank, HUNT, and Partners Biobank studies showed consistency across all three cohorts ( Supplementary Table 2 ). Next, to investigate the effects of genetic variants on objective sleep patterns, we tested the 57 lead variants for association with eight activity-monitor sleep measures in a subset of the UK Biobank participants of European ancestry who had undergone up to 7 d of wrist-worn accelerometry 
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(n = 84,745; Supplementary Table 6 ). The lead MEIS1 risk variant was associated with a higher number of sleep episodes, thus indicating an interrupted sleep pattern, lower sleep efficiency, shorter sleep duration, and later sleep timing (P < 0.0008; Supplementary  Table 9 ). The GRS was associated with lower sleep efficiency (difference = -0.04 (0.01) percent per allele; P = 4 × 10 −14 ), shorter sleep duration (difference = -0.25 (0.035) minutes per allele; P = 8 × 10 −13 ), and greater day-to-day variability in sleep-duration (difference = 0.077 (0.025) minutes per allele; P = 0.0017) but not with the number of sleep episodes or diurnal inactivity duration (Table 1 and Supplementary Table 9 ). To gain insight into the probable causal variants underlying the 57 association signals, we performed fine-mapping in probabilistic identification of causal SNPs (PICS) 21 and identified 38 variants with LD Score regression estimates of genetic correlation (r G ) of frequent insomnia symptoms, compared with the summary statistics from 224 publicly available genome-wide association studies of psychiatric and metabolic disorders, immune diseases, and other traits of natural variation. Blue, positive genetic correlation; red, negative genetic correlation, r G values are displayed for significant correlations. Larger squares correspond to more significant P values. Genetic correlations that are significantly different from zero after Bonferroni correction are shown on the plot (after Bonferroni correction, P-value cutoff of 0.0002). All genetic correlations in this report can be found in tabular form in Supplementary Table 19 . IQ, intelligence quotient.
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c d e f a causal probability of 0.20 or greater 22 ( Supplementary Table 10 and Supplementary Fig. 4 ). This list included missense variants in NADK (encoding NAD kinase p.Asn262Lys) and MDGA1 (p.Leu61Pro), as well as rs324017, a SNP within NAB1 (encoding the transcriptional repressor EGR-1-binding protein), which is predicted to disrupt a binding site for EGR1 ( Supplementary Table 10 ), a transcription factor involved in response to stress 23 and synaptic plasticity during rapid-eye-movement sleep 23 . The 57 insomnia-symptom-associated loci lie in genomic regions encompassing as many as 236 genes, and a summary of annotations for signals or genes within each locus is shown in Supplementary  Table 11 . The association signals at 14 loci overlapped with National Human Genome Research Institute GWAS signals (r 2 > 0.7 in 1000 Genomes Project CEU) for one or more complex traits. The insomnia-symptom risk allele was associated with a greater risk of restless legs syndrome (RLS), schizophrenia, Tourette's syndrome, or obsessive-compulsive disorder, and was also associated with higher systolic blood pressure, greater carotid-plaque burden, and lower age at menarche; moreover, it influenced adiposity traits, height, and educational attainment. Notably, experimental studies in mouse or fly models have implicated five genes at three associated loci in sleep regulation (DVL1, LRP1, NR1H3, PRKAR2A, and SEMA3F). Genes within 16 loci are known drug targets.
Two lead SNPs were associated with one or more of 3,144 human-brain structure and function traits assessed in the UK Biobank (P < 2.8 × 10 −7 , n = 9,707; Oxford Brain Imaging Genetics Server) 24 , including rs1544637 (within transcript LOC102723323) with several large white-matter tracts and with cingulate gyrus morphometry, which has previously been connected to insomnia 25 , and rs62158170 (near PAX8) with resting-state functional magnetic resonance imaging networks ( Supplementary Fig. 5 ).
Gene-based tests 26 identified 135 associated genes (P ≤ 2.29 × 10 −6 ; Supplementary Table 12 ). These genes showed enriched expression in brain regions 9 ( Supplementary Table 13 ) including the cerebellum (P = 1.3 × 10 −6 ), frontal cortex (P = 1.3 × 10 −5 ), anterior cingulate cortex (P = 1.7 × 10 −5 ), hypothalamus (P = 2.2 × 10 −5 ), basal ganglia (P = 7.0 × 10 −4 ), amygdala (P = 3.4 × 10 −4 ), and hippocampus (P = 8.4 × 10 −4 ), in line with previous research linking these brain regions to insomnia 25, 27 and with mouse single-cell studies linking insomnia GWAS hits to specific populations of brain cells 28 . Integration of gene expression data with GWAS through transcriptome-wide association analyses 29 identified 24 genes for which insomnia SNPs influenced gene expression in one or more of the 14 tissue types tested, including eight brain regions, muscles, peripheral nerves, whole blood, and pituitary, thyroid, and adrenal gland tissue (Supplementary Table 16 ).
The SNP-based heritability of frequent insomnia symptoms has been estimated at h 2 = 16.7% (ref. 30 ). Partitioning of heritability across tissue types 31, 32 confirmed enrichment in the central nervous system, adrenal/pancreas tissue, and skeletal muscle (P < 10 −5 ; Supplementary  Table 17 ). Partitioning across functional class implicated activation and repression of enhancers ( Supplementary Table 17 ). Pathway and ontology analyses 26, 33, 34 revealed a significant role of ubiquitin-mediated proteolysis (P bonf = 0.04; Supplementary Table 14 ), a result similar to findings in recent GWAS of RLS 35 and suggestive of roles for phototransduction and muscle tissue development, across several databases ( Supplementary Tables 14 and 15 ). Evidence from model organisms supports the link between Cullin-3-mediated ubiquitination and sleep/circadian rhythms [36] [37] [38] [39] . Furthermore, the RLS-associated gene BTBD9 has been implicated as a substrate adaptor for E3 ubiquitin ligases 40 . We found no evidence of enrichment of neurotransmissionreceptor or biosynthesis genes known to be involved in the regulation of sleep (for example, GABA, glutamate, or adenosine).
We investigated the genetic link between frequent insomnia symptoms and other behavioral and/or disease states. On the basis of previous links between RLS and insomnia symptoms 15, 16 , we tested a GRS of 20 SNPs for RLS 35 and found association with frequent insomnia symptoms (OR = 1.03 (1.02-1.04) per RLS risk allele, P = 2.57 × 10 −57 ), driven partly by the MEIS1 region (GRS excluding the MEIS1 region OR = 1.02 (1.02-1.03) per RLS risk allele, P = 2.06 × 10 −31 ; Supplementary Table 18 and Supplementary Fig. 6 ). We also tested a GRS of our 57 insomnia SNPs in RLS and found an association with RLS (OR = 1.39 (1.34-1.44), P = 1.70 × 10 −80 ) driven partly by the MEIS1 signal (GRS excluding the MEIS1 region OR = 1.17 (1.13-1.21), P = 2.56 × 10 −20 ; Supplementary Table 18 ). We also observed a positive genetic correlation between insomnia and RLS (r g = 0.291, P = 6.33 × 10 −12 ). We performed BUHMBOX (breaking up heterogeneous mixture based on cross-locus correlations) analysis to distinguish between pleiotropy and heterogeneity. BUHMBOX 41 analyses using all 20 RLS SNPs indicated heterogeneity (P = 4.09 × 10 −6 ), probably as a result of undiagnosed RLS cases misclassified as insomnia. However, when we excluded the MEIS1 locus, we detected a possible shared genetic basis not explained by heterogeneity (P = 0.137).
To test the proportion of variance that frequent insomnia symptoms share with other traits on the basis of genetic overlap, we performed genetic correlation analyses with 233 traits with public GWAS summary statistics 31, 32, 42, 43 . We found strong positive genetic correlations (P ≤ 2 × 10 −3 ) between frequent insomnia symptoms and adiposity traits, coronary artery disease (CAD), number of children ever born, neuroticism, smoking behavior, and depressive symptoms and disorders. Strong negative genetic correlations were observed with self-reported sleep duration, subjective well-being, cognitive measures, proxy longevity measures, and the remaining reproductive traits ( Fig. 2 and Supplementary Table 19 ). These genetic links persisted in GWAS excluding subjects with chronic and psychiatric illnesses ( Supplementary Table 19 ), thus indicating a relationship not driven by the presence of concomitant conditions.
To test for causal links between frequent insomnia symptoms and seven clusters of genetically correlated traits, we performed Mendelian randomization (MR) analyses mostly within a twosample summary data framework. Using the inverse-variance weighted (IVW) method 44 (Fig. 3 and Supplementary Table 20 ), we found evidence of a causal association (P < 0.001) between frequent insomnia symptoms and prevalent CAD (OR (95%CI) = 2.15 (1.38-3.35)), diminished subjective well-being (difference in mean s.d. units of -0.29 (s.e. 0.06)), and greater depressive symptoms (difference in mean s.d. units of 0.42 (s.e. 0.08)); all associations had a consistent direction and similar magnitude of effect in sensitivity analyses, as compared with the results from MR-Egger 45 and weighted-median methods 46 (Fig. 3 and Supplementary Table 20 ). We found similar results by using effect estimates from GWAS, excluding individuals with preexisting conditions. We validated the causal association between insomnia and CAD with one-sample MR in the UK Biobank (n = 23,980 cases and 361,706 controls, OR (95%CI) = 2.95 (2.18-3.99), P = 2.3 × 10 −12 ; Supplementary Table 20 and Supplementary Fig. 7 ). Bidirectional MR indicated no evidence of reverse causality between CAD and insomnia symptoms. The one-sample MR causal association between insomnia status and CAD in the UK Biobank is consistent with the robust empirical evidence seen in prospective studies and meta-analyses 3, 47 .
This study provides a comprehensive description of the genetic architecture of frequent or persistent insomnia symptoms, and indicates putative causal variants and candidate genes, pathways, and tissues for functional studies. Furthermore, we define physiological correlates for insomnia symptoms and meaningful clinical links, including a causal link with CAD.
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were feeling depressed or down for at least a whole week?" or "Have you ever had a time when you were uninterested in things or unable to enjoy the things you used to for at least a whole week?" with self-reported duration of symptoms lasting for more than 1 week. (v) Questionnaire-assessed bipolar disorder (Smith algorithm), with a response of "yes" to the question "Have you ever had a period of time lasting at least 2 days when you were feeling so good, 'high' , excited, or 'hyper' that other people thought you were not your normal self, or you were so 'hyper' that you got into trouble?" or "Have you ever had a period of time lasting at least 2 days when you were so irritable that you found yourself shouting at people or starting fights or arguments?" with self-reported duration of symptoms lasting at least 1 week and with at least three manic/hyper symptoms 50 . A list of sleep medications can be found in the Supplementary Note.
A description of CAD and activity-monitor-derived measures of sleep in the UK Biobank can be found in the Supplementary Note.
Genotyping and quality control. Phenotype data are available for 502,631 subjects in the UK Biobank. Genotyping was performed by the UK Biobank, and genotyping, quality control (QC), and imputation procedures have been described in detail 51 . In brief, blood, saliva, and urine were collected from participants, and DNA was extracted from the buffy-coat samples. Participant DNA was genotyped on two arrays, UK BiLEVE and UKB Axiom, with >95% common content, and genotypes for ~800,000 autosomal SNPs were imputed to two reference panels. Genotypes were called with Affymetrix Power Tools software. Samples and SNPs for QC were selected from a set of 489,212 samples across 812,428 unique markers. Sample QC was conducted with 605,876 high-quality autosomal markers. Samples were removed for high missingness or heterozygosity (968 samples) and sex chromosome abnormalities (652 samples). Genotypes for 488,377 samples passed sample QC (~99.9% of total samples). Marker-based QC measures were tested in the European-ancestry subset (n = 463,844), which was identified on the basis of principal components of ancestry. SNPs were tested for batch effects (197 SNPs per batch), plate effects (284 SNPs per batch), Hardy-Weinberg equilibrium (572 SNPs per batch), sex effects (45 SNPs per batch), array effects (5,417 SNPs), and discordance across control replicates (622 on the UK BiLEVE Axiom array and 632 on the UK Biobank Axiom array) (P < 10 −12 or < 95% for all tests). For each batch (106 batches total), markers that failed at least one test were set to missing. Before imputation, 805,426 SNPs passed QC in at least one batch (>99% of the array content). Population structure was captured by principal component analysis on the samples, by using a subset of high-quality (missingness <1.5%), high-frequency SNPs (>2.5%) (~100,000 SNPs), and the subsample of white British descent was identified. We further clustered subjects into four ancestry clusters by using kmeans clustering on the principal components, identifying 453,964 subjects of European ancestry. Imputation of autosomal SNPs was performed to UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference Consortium with the current analysis, by using only those SNPs imputed to the Haplotype Reference Consortium reference panel. Autosomal SNPs were prephased with SHAPEIT3 (ref. 52 ) and imputed with IMPUTE4. In total ~96 million SNPs were imputed. Related individuals were identified by estimating kinship coefficients for all pairs of samples, by using only markers weakly informative of ancestral background. In total, there were 107,162 related pairs comprising 147,731 individuals related to at least one other subject in the UK Biobank.
Genome-wide association analysis. Genetic association analysis across the autosomes was performed in related subjects of European ancestry (n = 453,964) with BOLT-LMM 30 linear mixed models and an additive genetic model adjusted for age, sex, ten principal components, genotyping array, and genetic correlation matrix, with a maximum per SNP missingness of 10% and per-sample missingness of 40%. We used a genome-wide-significance threshold of 5 × 10 −8 for each GWAS. To determine SNP effects on self-reported insomnia symptoms, we also performed genetic association analysis in unrelated subjects of white British ancestry (n = 337,545) with PLINK 53 logistic regression and an additive genetic model adjusted for age, sex, ten principal components, and genotyping array. We used a hard-call genotype threshold of 0.1, a SNP imputation-quality threshold of 0.80, and a MAF threshold of 0.001. Genetic association analysis for the X chromosome was performed with the genotyped markers on the X chromosome with the additional -sex flag in PLINK. We were 80% powered to detect a relative difference of 4% or more (that is, an OR of 1.04 or 0.96, assuming a MAF of 0.1, P = 5 × 10 −8 ). We performed sex-specific GWAS in PLINK 1.9 with logistic regression stratified by sex, adjusting for age, ten principal components of ancestry, and genotyping array. We used a hard-call genotype threshold of 0.1, a SNP imputation quality threshold of 0.80, and a MAF threshold of 0.001. SNP × sex interactions (13 tests) and SNP × menopause interaction in females (13 tests) were tested for genomewide-significant signals with the significance threshold defined by Bonferroni correction. SNP-based trait heritability was calculated as the proportion of trait variance due to additive genetic factors measured in this study with BOLT-REML 30 , to leverage the power of raw genotype data together with low-frequency variants (MAF ≥0.001). Additional independent risk loci were identified by using the approximate conditional and joint association method implemented in GCTA (GCTA-COJO) 54 . Fixed-effects meta-analysis was performed in METAL 55 with the standard-error scheme.
Sensitivity analyses on top signals. We performed follow-up analyses on genomewide-significant loci in the primary analyses, including covariate sensitivity analysis individually adjusting for sleep apnea, coffee/tea intake, physical activity, severe stress, depression, use of psychiatric medication, socioeconomic status, smoking, employment status, marital status, snoring, or BMI in addition to baseline adjustments for age, sex, ten principal components, and genotyping array. Sensitivity and sex-specific analyses were conducted only in unrelated subjects of white British ancestry.
Gene, pathway, and tissue-enrichment analyses. Gene-based analysis was performed in PASCAL 26 . Tissue enrichment analysis was conducted in FUMA 56 . Enrichment for pathways and ontologies was performed in EnrichR 33, 34 with the human genome as the reference set and a minimum number of two genes per category. A genetic risk score for RLS was tested by using the weighted genetic risk score calculated by summing the products of the RLS risk-allele count for 20 genome-wide-significant SNPs multiplied by the scaled RLS effect reported by Schormair et al. 35 , by using the summary statistics from our frequent-insomniasymptom GWAS and the GTX package in R 57 . Integrative transcriptome-wide association analyses with GWAS were performed with the FUSION TWAS package 29 , and weights were generated from gene expression in eight brain regions and six tissues from the GTEX consortium (v6), and SNPs common to the 1000 Genomes LD reference panel and our frequent-insomnia-symptom GWAS summary statistics. Tissues for TWAS testing were selected from the FUMA tissue enrichment analyses, and we presented significant results after Bonferroni correction for the number of genes tested per tissue and for all 14 tissues. The results table shows the number of individuals per tissue type used to generate expression weights, the total number of genes expressed per tissue, the gene symbol for the significant gene, the rsID for the best GWAS and eQTL SNPs in the reference panel, and the TWAS P value. GWAS and eQTL SNPs analyzed included only those SNPs present in the 1000 Genomes LD reference panel used by FUSION TWAS software; therefore, the best GWAS SNP listed in this table may be in strong linkage disequilibrium with, but not identical to, the lead GWAS SNP for hits in Supplementary Table 2 .
Heterogeneity analysis. Analyses to distinguish pleiotropy and heterogeneity between insomnia and RLS were performed with BUHMBOX 41 , which tests for the presence of heterogeneity between two traits. BUHMBOX analysis was performed in the insomnia GWAS, by using all 20 RLS SNPs and weights reported by Schormair et al. 35 and in the RLS GWAS, by using all 57 SNPs reported in Supplementary Table 2 . Additional sensitivity analyses were performed excluding SNPs in the MEIS1 region.
Genetic correlation analyses.
Post-GWAS genome-wide genetic correlation analysis of LD Score regression (LDSC) 32, 42, 43 by using LDHub was conducted on all UK Biobank SNPs also found in HapMap3, including publicly available data from 224 published genome-wide association studies, with a significance threshold of P = 0.002 after Bonferroni correction for all tests performed. LDSC estimates the genetic correlation between two traits from summary statistics (ranging from -1 to 1) on the basis of the incorporation of effects of all SNPs in LD with that SNP into the GWAS effect-size estimate for each SNP; SNPs with high LD had higher chi-square statistics than SNPs with low LD, and a similar relationship was observed when single study test statistics were replaced with the products of z scores from two studies of traits with some correlation. Furthermore, genetic correlation is possible between case-control studies and quantitative traits, as well as within these trait types. We performed partitioning of heritability by using the eight precomputed cell-type regions and 25 precomputed functional annotations available through LDSC, which were curated from large-scale robust datasets 31 . Enrichment both in the functional regions and in an expanded region ( + 500 bp) around each functional class was calculated to prevent the estimates from being biased upward by enrichment in nearby regions. The multiple testing threshold for the partitioning of heritability was determined by using conservative Bonferroni correction (P of 0.05/25 classes). Summary GWAS statistics will be made available at the UK Biobank web portal.
Mendelian randomization analyses. MR analysis was carried out with MR-Base 58 with the IVW approach as our main analysis method 44 , and with MR-Egger 45 and weighted-median estimation 46 as sensitivity analyses. MR results may be biased by horizontal pleiotropy, that is, when the genetic variants that are robustly related to the exposure of interest (here frequent insomnia symptoms) independently influence levels of a causal risk factor for the outcome. IVW assumes that there is no horizontal pleiotropy. MR-Egger provides unbiased causal estimates even if all the genetic instruments have horizontal pleiotropic effects, but it assumes that the association of genetic instruments with risk factor is not correlated with any pleiotropic genetic instrument associations with outcome. The weighted-median approach is valid if less than 50% of the weight is pleiotropic (that is, no single SNP that contributes 50% of the weight or a number of SNPs that together contribute 50% should be invalid because of horizontal pleiotropy. Given these different assumptions, our causal inference is strengthened if all three methods are broadly consistent. For most of our MR analyses, we used two-sample MR, in which, for all 57 of the insomnia GWAS hits identified in this study, we looked for the per-allele difference in odds (binary outcomes) or means (continuous) with outcomes from publicly available summary data in the MR-Base platform. The results are therefore a measure of 'any insomnia' , and sample 1 is UK Biobank (our GWAS), whereas sample 2 is a number of different GWAS consortia covering the outcomes that we explored ( Supplementary Table 17 ). For all four of the longevity outcomes and as follow up for CAD, we used one-sample MR with the SNP-outcome associations also obtained from UK Biobank. If we did not find one of the 57 SNPs in the outcome database, we substituted for a proxy where possible; LD proxies were defined by using the 1000 Genomes European sample with r 2 > 0.8. The number of SNPs used in each MR analysis varied by outcome from 11 to 53 because of some SNPs (or proxies for them) not being located in the outcome GWAS (Table 1) .
Primary association analyses of the 57 genome-wide-significant insomnia SNPs with CAD were performed in Hail (https://github.com/hail-is/hail/) by using imputed genotype dosages and a logistic regression model adjusting for age at first visit, sex, genotyping array, and the first ten principal components of ancestry. A total of 23,980 CAD cases were compared to 388,326 referents. For MR, a fixedeffects IVW meta-analysis was performed of the SNP-specific association estimates with CAD, by aligning each insomnia SNP allele/β coefficient to 'increased risk of insomnia' . Sensitivity analyses were performed by excluding the variants with the strongest effect estimate and/or widest confidence intervals to account for SNP heterogeneity.
Replication cohort. Replication-cohort sample ascertainment, phenotype definition, genotyping, QC, imputation, and analyses are described in the Supplementary Note.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
All data was collected by the UK Biobank, HUNT study, and Partners Biobank. This is a secondary use of data.
Data analysis
The following softwares were used: R 3.12, BOLT-LMM 2.3.2, PLINK 1.9, LocusZoom 0.4.8, omconvert, FUSION TWAS, Affymetrix Power Tools 1.16.1, MRbase 1.2.1, LDhub 1.9.0, LDSC 1.0.0, FUMA 1.3.3, MS Office2016, SHAPEIT3, Impute4, METAL 2011-03-25, GCTA 1.90.0, and Pascal. We used no custom code.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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